Challenges of NK cell-based immunotherapy in the new era  

作　　者：Fang Fang Weihua Xiao Zhigang Tian 

机构地区：[1]Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Signaling Network, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei 230027, China [2]Hefei National Laboratory for Physical Sciences at Microscale, Hefei 230027, China

出　　处：《Frontiers of Medicine》2018年第4期440-450,共11页医学前沿（英文版）

基　　金：This work was supported by the National Natural Science Foundation of China （Nos. 81788101, 91542000, 81671558, and 31571440）; the Ministry of Science and Technology of China （No. 2016YFC1303503） and Chinese Academy of Sciences （Nos. XDA12020312, XDPB030301, and XDPB030303）.

摘　　要：Natural killer cells （NKs） have a great potential for cancer immunotherapy because they can rapidly and directly kill transformed cells in the absence of antigen presensitization. Various cellular sources, including peripheral blood mononuclear cells （PBMCs）, stem cells, and NK cell lines, have been used for producing NK cells. In particular, NK cells that expanded from allogeneic PBMCs exhibit better efficacy than those that did not. However, considering the safety, activities, and reliability of the cell products, researchers must develop an optimal protocol for producing NK cells from PBMCs in the manufacture setting and clinical therapeutic regimen. In this review, the challenges on NK cell-based therapeutic approaches and clinical outcomes are discussed.Natural killer cells （NKs） have a great potential for cancer immunotherapy because they can rapidly and directly kill transformed cells in the absence of antigen presensitization. Various cellular sources, including peripheral blood mononuclear cells （PBMCs）, stem cells, and NK cell lines, have been used for producing NK cells. In particular, NK cells that expanded from allogeneic PBMCs exhibit better efficacy than those that did not. However, considering the safety, activities, and reliability of the cell products, researchers must develop an optimal protocol for producing NK cells from PBMCs in the manufacture setting and clinical therapeutic regimen. In this review, the challenges on NK cell-based therapeutic approaches and clinical outcomes are discussed.

关 键 词：natural killer cells IMMUNOTHERAPY adoptive transfer genetic modification immune checkpoint inhibitor 

分 类 号：S858.325.3[农业科学—临床兽医学] TU831.7[农业科学—兽医学]